Strides Pharma Science · NSE: STAR · BSE: 532531

Q1 FY23 results · Apr–Jun 2022

Strides Pharma Science reported revenue from operations of ₹940.07 crore (up 36.6% from Q1 FY22) and net loss of ₹135.33 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	940.07	688.37	+36.6%	866.02	+8.6%
Other income	13.55	13.53	+0.1%	86.06	−84.3%
Total income	953.62	701.90	+35.9%	952.08	+0.2%
Profit before share of associates & JVs and tax	(107.01)	(224.58)	Loss narrowed	(58.88)	Loss widened
Share of profit/(loss) of associates & JVs	(56.39)	(19.53)		(43.64)
Net profit for the period	(135.33)	(208.57)	Loss narrowed	28.96	Turned loss
Attributable to shareholders of the company	(135.89)	(205.20)	Loss narrowed	29.22	Turned loss
EPS, basic (₹)	(15.13)	(22.88)	Loss narrowed	3.25	Turned loss
Net margin (%)	-14.4	-30.3		3.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	423.19	508.79	−16.8%	455.66	−7.1%
Other income	7.46	8.75	−14.7%	84.83	−91.2%
Total income	430.65	517.54	−16.8%	540.49	−20.3%
Profit before tax	(103.88)	(27.79)	Loss widened	56.71	Turned loss
Net profit for the period	(66.25)	(21.23)	Loss widened	200.50	Turned loss
EPS, basic (₹)	(7.38)	(2.37)	Loss widened	22.33	Turned loss
Net margin (%)	-15.7	-4.2		44.0

Consolidated

Filed with BSE: 30 Jul 2022, 11:33 IST
Board meeting: 29 Jul 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jul 2022, 11:33 IST
Board meeting: 29 Jul 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE